About Rab GDP dissociation inhibitor alpha
Rab GDP dissociation inhibitor alpha (GDI1) is a protein
from Homo sapiens identified by UniProt accession
P31150, 447 residues long.
MolForge cross-references it against 0 known binders and
162 disease associations.
Target properties
| Protein name | Rab GDP dissociation inhibitor alpha |
| UniProt accession | P31150 |
| Gene | GDI1 |
| Organism | Homo sapiens |
| Length | 447 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (162)
Diseases linked to this target (Open Targets).
- X-linked non-syndromic intellectual disability · score 0.74
- Intellectual disability · score 0.37
- multiple sclerosis · score 0.34
- Parkinson disease · score 0.34
- lysosomal storage disease · score 0.34
- Alzheimer disease · score 0.34
- neurodegenerative disease · score 0.34
- genetic disorder · score 0.33
- non-syndromic X-linked intellectual disability · score 0.31
- cardiac hypertrophy · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P31150-F1 | alphafold | PREDICTED | 93.36 | — |
Amino-acid sequence (447 residues)
MDEEYDVIVL GTGLTECILS GIMSVNGKKV LHMDRNPYYG GESSSITPLE ELYKRFQLLE GPPESMGRGR DWNVDLIPKF LMANGQLVKM LLYTEVTRYL DFKVVEGSFV YKGGKIYKVP STETEALASN LMGMFEKRRF RKFLVFVANF DENDPKTFEG VDPQTTSMRD VYRKFDLGQD VIDFTGHALA LYRTDDYLDQ PCLETVNRIK LYSESLARYG KSPYLYPLYG LGELPQGFAR LSAIYGGTYM LNKPVDDIIM ENGKVVGVKS EGEVARCKQL ICDPSYIPDR VRKAGQVIRI ICILSHPIKN TNDANSCQII IPQNQVNRKS DIYVCMISYA HNVAAQGKYI AIASTTVETT DPEKEVEPAL ELLEPIDQKF VAISDLYEPI DDGCESQVFC SCSYDATTHF ETTCNDIKDI YKRMAGTAFD FENMKRKQND VFGEAEQ
Explore Rab GDP dissociation inhibitor alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets